The value of MBMA for determining best-in-class
Why Model-Based Meta-Analysis is one of the most useful tools for determining whether a drug pathway has hit its ceiling — and whether a best-in-class molecule is still achievable before you invest in optimization.
Target occupancy — how you define it can make or break your drug
Why 100% target occupancy can be misleading for soluble targets — total target accumulation reflects binding, not the free-target reduction that actually drives therapeutic effect, and how the two can diverge based on complex vs. target half-life.
Translating biologics PK from preclinical species to humans
A practical breakdown of the approaches for translating biologics PK from preclinical species to humans — from full PBPK to minimal and site-of-action models — and how to pick the right one for your program.